Insulin illustrates a basic problem in health economics:
Need does not guarantee access
People can require a drug to stay alive, yet still struggle to afford it. Why? Because prices and out-of-pocket costs are shaped by:
1. Inelastic demand
2. Insurance benefit design
3. The drug supply chain
The main skill in this module is making trade-offs explicit.
In healthcare, budgets are finite. If you spend money on one thing, you are choosing not to spend it elsewhere. This is opportunity cost.
Learning Targets
Explain (in plain language) why insulin demand is inelastic and how that affects affordability.
Draw the insulin pathway (Manufacturer → PBM → Plan → Pharmacy → Patient) and label the decision points that determine what patients pay.
Defend a clinic budget decision using one back-of-the-envelope calculation (BOTE), one Iron Triangle trade-off (Access-Quality-Cost), and one clear opportunity cost sentence.
Check Your Understanding
Opportunity cost is:
It's what you sacrifice by choosing one option over another.
Demand is inelastic when:
With insulin, people often can't safely "buy less."
If insulin demand is inelastic, higher prices are more likely to:
Inelastic demand means people can't easily reduce consumption, so higher prices create financial stress rather than reducing need.
The Iron Triangle is:
The Iron Triangle represents the three competing priorities in healthcare: Access, Quality, and Cost.
Content
1) Opportunity cost (how economists use it)
Opportunity cost is the best alternative you give up when you choose something.
Budget Decision Example
+
Choose X-ray Machine
Diagnostic capability
⇄
−
Give Up Community Health Workers
Preventive outreach foregone
The opportunity cost is what you give up — not the price paid
"If we fund X, we cannot fund Y."
2) Inelastic demand (why insulin pricing is different)
What happens when insulin price rises
Price ↑↑
Insulin becomes more expensive
Demand →
Need stays the same — patients still require it
Result: financial stress or reduced access — not reduced medical need
Demand is inelastic when people cannot easily reduce consumption as price rises. With insulin, many patients cannot safely buy less. High prices therefore tend to reduce access (or create financial stress) instead of reducing the underlying need.
3) The Iron Triangle: Access, Quality, Cost
Use this framework to keep arguments honest:
Improving one corner often pressures the others
Access
Who can get care and how easily
Quality
Effectiveness and patient outcomes
Cost
Spending by patients and payers
trade-offs run in all directions
Many real policies improve one corner by pressuring at least one other corner.
4) Insulin basics (only what you need for this case)
Insulin Types by Duration of Action
Rapid-acting
3–5 hrs
Short / Regular
5–8 hrs
Intermediate
12–18 hrs
Long-acting
20–24+ hrs
Approximate durations — actual times vary by specific product
Insulin types are commonly grouped by how fast they start and how long they last (rapid-acting, short/regular, intermediate, long-acting, and premixed).
Analog insulins are modified versions designed to change how quickly and how long insulin acts.
Key point: Patients do not always have perfect substitutes
Plans often treat some products as preferred and others as non-preferred.
5) The insulin pathway and decision points
The Insulin Supply Chain
Manufacturer
Sets list price
→
PBM
Builds formulary
→
Insurer / Plan
Sets benefits
→
Pharmacy
Dispenses drug
→
Patient
Pays OOP cost
Note: This is a simplified pathway; wholesalers and employers also play roles, but we're focusing on the main decision points that shape what patients pay.
Label these decision points on your map:
Manufacturer: Sets a list price and negotiates contracts/discounts.
PBM: Builds the formulary (covered drugs and tiers) and negotiates rebates/fees with manufacturers.
Important: Rebates are negotiated behind the scenes and don't necessarily lower what a patient pays at the counter.
Insurer/Plan: Sets the deductible, copay vs coinsurance, tiering, and rules like prior authorization or step therapy.
Pharmacy: Dispenses the product and collects the patient's cost-sharing at the counter.
6) Key vocabulary for the case
Formulary: the plan's list of covered drugs.
Tier: preferred drugs cost less; non-preferred cost more.
Deductible: amount paid before coverage reduces cost.
Copay vs coinsurance: fixed dollar vs percent of price.
Prior authorization / step therapy: extra approval or "try this first" requirement.
7) Why a cap does not always equal access
Caps can reduce what patients pay in specific programs, but they usually do not apply to everyone or to every situation. A cap helps only when:
The patient is in the program that has the cap
The product is covered
Plan rules do not block access (e.g., a non-preferred tier or prior authorization)
The cap applies in the part of the benefit the patient is in (some caps don't apply before the deductible).
Check Your Understanding
Which sequence matches the module's insulin pathway?
The pathway flows from Manufacturer through intermediaries (PBM, Insurer/Plan, Pharmacy) to reach the Patient.
A formulary is:
A formulary is the list of drugs covered by an insurance plan, organized by tiers.
A tier refers to:
Tiers categorize drugs by cost-sharing, with preferred drugs having lower out-of-pocket costs.
Case Study
Insulin Cap, But the Wall Is Still There
Scenario
Assume a cap exists for certain insured groups, but two patients still face barriers. Use your pathway map to explain where the system blocks them.
Patient Profile A: High deductible
Jordan has employer insurance with a $2,500 deductible. In January and February, Jordan's out-of-pocket cost is high because the plan requires paying most of the cost until the deductible is met.
Students must answer:
On your map, circle the decision point that created this barrier (Plan design: deductible).
Write one sentence explaining why a cap in some programs does not automatically help Jordan.
Marisol uses an analog insulin that is non-preferred on her plan. The plan requires a switch (step therapy) or prior authorization. Staying on the current insulin leads to much higher cost-sharing.
Students must answer:
On your map, circle: PBM formulary/tier and Plan coverage rules.
Write one sentence explaining how coverage can exist while access is still blocked.
Case questions:
For each patient, identify two decision points that most affect what they pay.
Name one fix that lowers cost and the trade-off it creates (Iron Triangle).
Decide: is the barrier mostly price, coverage, or benefit design? Defend your answer.
Check Your Understanding
Jordan has a $2,500 deductible and pays a lot early in the year. Which decision point most directly creates this barrier?
Jordan's high deductible is a feature of the insurance plan's benefit design.
Marisol's analog insulin is non-preferred and requires step therapy/prior authorization. Which two decision points most directly drive this barrier?
The PBM determines the formulary tiers, and the plan sets coverage rules like prior authorization.
A cap helps only when:
Caps have specific eligibility requirements and don't help if coverage or access barriers exist.
Activity
Clinic Budget Simulation (Mock City Council)
You have $50,000 for one major improvement this year. Choose one:
One simple number (a back-of-the-envelope calculation)
One Iron Triangle trade-off (Access, Quality, Cost)
One opportunity cost sentence: "If we choose X, we give up Y."
BOTE note: We're using purchase cost only and ignoring ongoing operating costs/overhead to keep the math simple.
Sample BOTE calculations:
If you choose X-ray:
Cost per scan = $50,000 / 1,920 ≈ $26/scan
Referrals avoided = 1,920 × 30% = 576/year
If you choose CHWs:
Cost per touch = $50,000 / 960 ≈ $52/touch
Or estimate savings from fewer no-shows/ER visits
Iron Triangle prompts:
X-ray: Access improves for diagnostics; quality may improve via faster diagnosis; cost is a large fixed expense; you give up community prevention/navigation work.
CHWs: Access improves for navigation and follow-through; quality may improve for chronic care; you give up faster in-house diagnostics.
Module Output (1 page)
Students submit:
A supply chain map with decision points labeled (manufacturer / PBM formulary / plan deductible and tier / pharmacy counter).
A 6-8 sentence City Council statement that includes: their choice, their BOTE number, one Iron Triangle trade-off, and the opportunity cost sentence.
The required table below:
Choice
Key benefit (Access/Quality)
Key cost/trade-off
Your BOTE number
What you give up
X-ray
CHWs
Check Your Understanding
Using the module's assumptions: 12 scans/day × 4 days/week × 40 weeks/year =
12 × 4 × 40 = 1,920 scans per year capacity for the X-ray machine.
Using the module's assumptions: 2 CHWs × 12 clients/week × 40 weeks/year =
2 × 12 × 40 = 960 clients per year capacity for the Community Health Workers.